CMS Clawbacks Create Chaos, Forcing Sanuwave into a Strategic Gamble

EDEN PRAIRIE, Minn. – June 16, 2026 – When a CEO admits there’s “near-term wood to chop,” it’s a clear signal that the ground has shifted beneath a company’s feet. For Sanuwave Health, that shift feels more like a seismic event. The wound care device maker announced today it was cutting its second-quarter revenue guidance, expecting between $8.5 and $9.5 million—a notable drop from projections made just last month. The reason, according to CEO Morgan Frank, is a series of “material changes” in the capital equipment market.

But this is more than the story of one company’s difficult quarter. Sanuwave’s announcement is a flare sent up from the front lines of the American healthcare industry, revealing a chaotic ripple effect triggered by government policy changes. It’s a story of how a cost-cutting measure in Washington D.C. can shutter clinics in Minnesota, spawn an unregulated secondary market for sophisticated medical devices, and force a public company into a high-stakes pivot to survive.

The Unraveling of a Market

The source of Sanuwave’s pain can be traced directly back to the Centers for Medicare & Medicaid Services (CMS). Effective January 1, 2026, the agency radically altered how it reimburses for skin substitutes and allografts, crucial components of advanced wound care. Previously, many of these products were paid for under an Average Sales Price (ASP) model, allowing for varied pricing. Now, they are largely classified as “incident-to medical supplies,” subject to a uniform, flat-rate national payment of around $127 per square centimeter.

CMS’s goal was explicit: to curb what it called a “dramatic” explosion in spending, which had ballooned from $250 million in 2019 to an estimated $10 billion by 2024. The agency projects its new policy will slash Medicare spending on these products by nearly 90%, saving an estimated $19.6 billion this year alone. For the government, it’s a massive fiscal correction. For the wound care clinics on the ground, it’s a financial catastrophe.

These clinics, particularly smaller physician-owned practices, saw their margins evaporate overnight. The new flat rate often fails to cover the acquisition costs of the very products they need to treat patients. As Morgan Frank stated in his press release, these widespread clawbacks “have been coming in far worse than many seem to have expected and this has been driving a number of wound care practices out of business.” This isn't just corporate-speak; it’s the sound of a market segment collapsing under regulatory pressure.

The Cannibalization Effect

When a business fails, its assets are liquidated. In the wound care industry, those assets include sophisticated and expensive capital equipment, like Sanuwave’s flagship Ultramist system. This has given rise to an unintended and highly disruptive consequence: a burgeoning secondary market for used medical devices.

Frank was blunt about the impact, noting that clinic closures are “resulting in used Ultramist systems for sale in the marketplace and this has had a significant cannibalization effect on the market for new systems.”

For Sanuwave, this is a direct blow to a core revenue stream. A new Ultramist system represents a significant capital sale. A used system, sold from one distressed clinic to another, generates nothing for the manufacturer. Practices that might have been future customers for new equipment are now finding a cheaper alternative born from the failure of their peers. This dynamic is the primary driver behind the company’s revised guidance and represents a fundamental threat to its traditional business model.

A Strategic Pivot to Survival

Faced with a shrinking market for new equipment, Sanuwave is making a bold and risky strategic pivot. The company is choosing to embrace the chaos. Frank’s declaration, “in the end, we’re in the applicator business,” is the tell. This isn’t about selling boxes; it’s about selling the high-margin, recurring-revenue consumables that go with them.

The company’s new strategy is to “lean in to qualify, train, and support new users” of Ultramist systems, regardless of where they acquired the device. The logic is sound: every system in operation, whether new or used, is a potential lifelong customer for the disposable applicators required for each treatment. While capital sales are down, Sanuwave noted that applicator volumes are on pace for a record quarter, proving the underlying demand for the therapy remains strong.

However, this path is fraught with peril. The company itself acknowledged the “regulatory, quality, and product-liability considerations” of this approach. Servicing a fleet of used devices of unknown age, condition, and maintenance history is an operational nightmare. It invites significant regulatory scrutiny from the FDA, which has strict rules on device servicing and refurbishment. Furthermore, it opens the company up to new liability risks. If a patient is harmed by a used device that Sanuwave has trained a new user on, the legal ramifications could be severe. The company is betting it can navigate this minefield to convert a threat into a larger, more stable annuity stream from consumables.

A Bellwether for Med-Tech

While the focus today is on Sanuwave, its story should serve as a cautionary tale for the entire medical device industry. The forces battering this one company are not unique. The dual pressures of aggressive government cost-containment and the resulting market disruptions are a new reality for any firm whose fortunes are tied to healthcare reimbursement.

The emergence of a robust secondary market fueled by provider failures is a trend that could easily spread to other specialties. Any med-tech firm reliant on lumpy capital sales to a customer base facing financial distress is vulnerable. Sanuwave’s experience demonstrates that a company’s fate is inextricably linked not just to its own execution, but to the financial health of its customers and the ever-shifting sands of public policy.

Sanuwave’s leadership is attempting to turn a crisis into a strategic evolution. By shifting focus from one-time hardware sales to recurring consumable revenue, they are embracing a model favored by Wall Street. But whether they can successfully manage the immense operational and legal complexities of this pivot remains the critical question. The wood has been identified; now comes the chopping.